Please login to the form below
Sylvant
This page shows the latest Sylvant news and features for those working in and with pharma, biotech and healthcare.
EC approves Janssen rare blood disorder drug
Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... The European Commission's decision to greenlight Sylvant comes
Latest news
-
FDA approves Janssen drug for rare Castleman’s disease
Due to the severity of the disease and lack of current treatment options Sylvant was assessed by the FDA under its priority review programme. ... Sylvant is also under review in the EU where Janssen submitted a drug filing in September last year. .
-
EMA backs Janssen rare disease drug for approval
Castleman's disease treatment Sylvant wins CHMP recommendation. J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe. ... Sylvant, which was filed for approval in Europe and the US
-
Boehringer/Lilly's empagliflozin among CHMP recommendations
There were also recommendations for four orphan drugs: Janssen-Cilag's Sylvant (situximab) and, along with the companion diagnostic drugs Folcepri (etarfolatide) and Neocepri (folic acid), Endocyte's Vynfinit (vintafolide).
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- Gut instincts lead Takeda to GI pipeline success
- How will the events and exhibitions industry change post-Coronavirus?
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Roche’s Tecentriq combo scores FDA approval for melanoma
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
- Virtual Reality in Medicine and Clinical Research
- J&J inks $1bn deal with US for coronavirus vaccine
- Novartis builds its case for novel MS treatment ofatumumab
- Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
